The Exclusion of Children from GLP-1 Trials in the U.S.

Obesity affects over 150 million Americans, with approximately 15 million children classified as obese. This condition significantly increases the risk of serious health issues, including Type 2 diabetes and cardiovascular disease. Despite the urgency to address childhood obesity, the development of anti-obesity medications for children has not kept pace with adult treatments. Currently, only semaglutide and liraglutide, both GLP-1 agonists, are FDA-approved for children aged 12 and older, with liraglutide offering less effective weight loss and requiring daily injections.

The Problem With Excluding Children From GLP-1 Trials In The U.S.

The exclusion of children from initial clinical trials for anti-obesity medications stems from the FDA's regulatory framework. Under the Pediatric Research Equity Act (PREA), pediatric studies are encouraged but not mandated unless the disease does not occur in children. This allows pharmaceutical companies to prioritize adult trials, deferring pediatric studies until after adult safety is established. Consequently, children may face delays in accessing effective treatments, with trials for medications like tirzepatide for ages 12 to 18 expected to conclude in 2027, while studies for younger children may not finish until 2030.

The Problem With Excluding Children From GLP-1 Trials In The U.S.

In contrast, the European Union mandates that all new drugs include a Pediatric Investigation Plan (PIP) as part of their marketing authorization process. This legal requirement ensures that pediatric studies are integrated into the drug development timeline, unlike the U.S. system, where such plans are merely suggested. As a result, the EU has seen more pediatric drug development initiatives than the U.S., highlighting a significant disparity in how childhood obesity is addressed in clinical research.

The Problem With Excluding Children From GLP-1 Trials In The U.S.

Critics argue that the current regulatory environment discriminates against children with obesity, leaving them without access to potentially life-saving medications. The arbitrary age distinctions in treatment availability raise questions about the rationale behind delaying pediatric trials. The lack of a Pediatric Study Plan for emerging treatments like retatrutide and maritide further underscores the neglect of this vulnerable population.

The Problem With Excluding Children From GLP-1 Trials In The U.S.

The FDA's recent draft guidance on obesity-drug development acknowledges the need for pediatric trials but stops short of making them mandatory. This has led to calls for a reevaluation of how clinical trials for children are conducted, emphasizing the need for timely access to new treatments for the 15 million children affected by obesity in the U.S.

The Problem With Excluding Children From GLP-1 Trials In The U.S.

As the childhood obesity epidemic continues to escalate, there is a pressing need for the FDA to reconsider its approach to pediatric clinical trials. The ongoing development of anti-obesity medications presents an opportunity to integrate children into research plans earlier, ensuring they benefit from advancements in treatment alongside adults.

The Problem With Excluding Children From GLP-1 Trials In The U.S.

• “The time has come for the FDA to rethink how it approaches clinical trials in children for the sake of the 15 million children with obesity — and really for all children ignored by the current regulatory environment.” — Evan P. Nadler, MD

The Problem With Excluding Children From GLP-1 Trials In The U.S.

• “Wouldn’t it have made more sense for the oral semaglutide trials to have included children down to age 12 since the injectable formulation is already approved for that age?” — Source Not Specified

The Problem With Excluding Children From GLP-1 Trials In The U.S.